US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArriVent BioPharma

21.26

+0.36001.72%

Pre-market: 21.620.3600+1.69%04:23 EDT

Volume:183.44K

Turnover:3.89M

Market Cap:723.18M

PE:-8.31

High:21.60

Open:20.48

Low:19.48

Close:20.90

Loading ...

Overview Company News Filings

Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

new option listings on April 9th

ArriVent BioPharma Initiated at Buy by Guggenheim

Guggenheim Initiates ArriVent BioPharma at Buy With $45 Price Target

MT Newswires Live

ArriVent BioPharma Price Target Maintained With a $39.00/Share by HC Wainwright & Co.

ArriVent BioPharma, Inc.: Promising Clinical Trials and Market Potential Reinforce Buy Rating

ArriVent BioPharma Reports 2024 Financial Results and Progress

ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024

Arrivent Biopharma Inc - Expects Cash to Fund Operations Into 2026

THOMSON REUTERS

ArriVent BioPharma Reports Full Year 2024 Financial Results

Arrivent Biopharma Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS

ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright

ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.

ArriVent BioPharma Expands Oncology Pipeline with New License

ArriVent BioPharma Enters Licensing Deal With Lepu Biopharma for Gastrointestinal Cancer Drug

MT Newswires Live

BUZZ-HK-listed Lepu jumps most in 5 weeks on exclusive deal with ArriVent BioPharma

BRIEF-Lepu Biopharma Says Exclusive License Agreement For Novel Adc Mrg007

BRIEF-Arrivent Biopharma Enters Exclusive License With Lepu Biopharma For Mrg007, An Antibody Drug Conjugate

Lepu Biopharma Co Ltd -Exclusive License Agreement for Novel ADC Mrg007

THOMSON REUTERS

Arrivent Biopharma Enters Exclusive License With Lepu Biopharma for Mrg007, an Antibody Drug Conjugate for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":21.26,"timestamp":1746043200000,"preClose":20.9,"halted":0,"volume":183437,"hourTrading":{"tag":"盘前","latestPrice":21.62,"preClose":21.26,"latestTime":"04:23 EDT","volume":6,"amount":125.509998,"timestamp":1746087831233},"delay":0,"floatShares":15839111,"shares":34016197,"eps":-2.557665,"marketStatus":"Pre-Mkt","change":0.36,"latestTime":"05-01 08:35:11 EDT","open":20.48,"high":21.6,"low":19.48,"amount":3886615.4766,"amplitude":0.101435,"askPrice":23.77,"askSize":100,"bidPrice":13.72,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.557665,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":21.26,"preHourTrading":{"tag":"盘前","latestPrice":21.62,"preClose":21.26,"latestTime":"04:23 EDT","volume":6,"amount":125.509998,"timestamp":1746087831233},"postHourTrading":{"tag":"盘后","latestPrice":21.26,"preClose":21.26,"latestTime":"16:22 EDT","volume":5661,"amount":120352.86,"timestamp":1746044521966},"volumeRatio":1.1833505091287777,"impliedVol":0.2628,"impliedVolPercentile":0.2},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":15839111,"roa":"-26.91%","roe":"-39.36%","lyrEps":-2.557665,"volumeRatio":1.1833505091287777,"shares":34016197,"dividePrice":0,"high":21.6,"amplitude":0.101435,"preClose":20.9,"low":19.48,"week52Low":15.47,"pbRate":"2.81","week52High":36.37,"institutionHeld":0,"latestPrice":21.26,"eps":-2.557665,"divideRate":0,"volume":183437,"delay":0,"ttmEps":-2.557665,"open":20.48,"prevYearClose":26.64,"prevWeekClose":20.82,"prevMonthClose":21.26,"prevQuarterClose":18.49,"fiveDayClose":21.08,"twentyDayClose":18.03,"sixtyDayClose":27.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530039724","title":"Press Release: ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530039724","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530039724?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"NEWTOWN SQUARE, Pa., April 28, 2025  -- ArriVent BioPharma, Inc.  , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc.\"Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies across a broad array of therapeutic areas,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"We are thrilled to have him join our Board of Directors at this important time and leverage his experience as firmonertinib progresses towards registration and we advance our antibody drug conjugate  pipeline.\". ArriVent is a clinical-stage biopha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","BK4080","AVBP"],"gpt_icon":0},{"id":"2526636636","title":"new option listings on April 9th","url":"https://stock-news.laohu8.com/highlight/detail?id=2526636636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526636636?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201816,"startTime":"0","endTime":"0","summary":"New option listings for April 9th include Alumis Inc (ALMS), LEVERAGE SHARES 2X LONG ASML DAILY ETF (ASMG), Arrivent Biopharma Inc (AVBP), REX BITC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/new-option-listings-on-april-9th?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/new-option-listings-on-april-9th?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","LU0823434583.USD","ASMG","LU2063271972.USD","LU0097036916.USD","LU0823434740.USD","LU0345774391.USD","LU1734074674.USD","BK4588","BK4147","BK4007","BK4543","LU0345774631.USD","BK4585","IE0004445239.USD","ALMS","03165","BK4139","FDN","BK4550","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2518279685","title":"ArriVent BioPharma Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518279685?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:11","pubTimestamp":1741619460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 11:11 ET (15:11 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2518280592","title":"Guggenheim Initiates ArriVent BioPharma at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2518280592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518280592?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:06","pubTimestamp":1741608411,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) has an average rating of buy and mean price target of $40.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVBP"],"gpt_icon":0},{"id":"2517438614","title":"ArriVent BioPharma Price Target Maintained With a $39.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438614?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:45","pubTimestamp":1741351500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:45 ET (12:45 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2517462486","title":"ArriVent BioPharma, Inc.: Promising Clinical Trials and Market Potential Reinforce Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517462486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517462486?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:28","pubTimestamp":1741346931,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) today and set a price target of $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-promising-clinical-trials-and-market-potential-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-promising-clinical-trials-and-market-potential-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0},{"id":"2516238616","title":"ArriVent BioPharma Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2516238616","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516238616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 12:03","pubTimestamp":1741061018,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q4 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","BK4139","AVBP","BK4097","PRGS"],"gpt_icon":0},{"id":"2516680176","title":"ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680176","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680176?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:20","pubTimestamp":1741004442,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44073766/arrivent-biopharma-2024-net-loss-80-5m-cash-cash-equivalent-and-investments-of-266-5m-as-of-dec-31-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2516687078","title":"Arrivent Biopharma Inc - Expects Cash to Fund Operations Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687078?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:10","pubTimestamp":1741003801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2516168726","title":"ArriVent BioPharma Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516168726","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516168726?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonert","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035450/0/en/ArriVent-BioPharma-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PACC","ADC","BK4231","AVBP","BK4080"],"gpt_icon":0},{"id":"2508112355","title":"Arrivent Biopharma Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112355","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112355?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:06","pubTimestamp":1738584399,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2505510097","title":"ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2505510097","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505510097?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:05","pubTimestamp":1737633950,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on ArriVent Biopharma  to $39 from $36 and keeps a Buy rating on the shares after the company entered into an exclusive license agreement with Lepu Biopharma. The firm says ArriVent’s portfolio continues to broaden with the MRG007 license.Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.ArriVent BioPharma Expands Oncology Pipeline with New License","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/arrivent-biopharma-price-target-raised-120550197.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrivent-biopharma-price-target-raised-120550197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVBP"],"gpt_icon":0},{"id":"2505774785","title":"ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2505774785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505774785?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:58","pubTimestamp":1737550680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2025 07:58 ET (12:58 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2505743484","title":"ArriVent BioPharma Expands Oncology Pipeline with New License","url":"https://stock-news.laohu8.com/highlight/detail?id=2505743484","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505743484?lang=en_us&edition=fundamental","pubTime":"2025-01-22 19:29","pubTimestamp":1737545370,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc. ( ($AVBP) ) has provided an announcement. On January 21, 2025, ArriVent BioPharma, Inc. entered into an exclusive license ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-expands-oncology-pipeline-with-new-license?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arrivent-biopharma-expands-oncology-pipeline-with-new-license?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2505972877","title":"ArriVent BioPharma Enters Licensing Deal With Lepu Biopharma for Gastrointestinal Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505972877","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505972877?lang=en_us&edition=fundamental","pubTime":"2025-01-22 16:46","pubTimestamp":1737535573,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma  said late Tuesday it has entered into an exclusive licensing agreement with Lepu Biopharma to develop and commercialize gastrointestinal cancer drug MRG007 outside of Greater China.Under the terms of the deal, Lepu Biopharma will get an upfront payment and near-term milestone payments totaling $47 million in cash and will be eligible to receive up to $1.16 billion in development, regulatory and sales milestones and tiered royalties on net sales outside of Greater China.The payments and research and development costs will not change ArriVent's expected cash runway into 2026, the company said.MRG007 has shown antitumor activity in preclinical models, the company said, adding that an investigational new drug submission is planned for H1.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2505594687","title":"BUZZ-HK-listed Lepu jumps most in 5 weeks on exclusive deal with ArriVent BioPharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2505594687","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505594687?lang=en_us&edition=fundamental","pubTime":"2025-01-22 10:19","pubTimestamp":1737512361,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Lepu jumps most in 5 weeks on exclusive deal with ArriVent BioPharma** Hong Kong-listed Lepu Biopharma 2157.HK jumps 14.2% to HK$2.73; set for biggest one-day pct gain since Dec. 17, 2024** Stock hits highest since Dec. 27, 2024; on track for fifth consecutive session of gains** Co grants exclusive global rights to ArriVent BioPharma AVBP.O to develop and commercialize Lepu's novel antibody drug conjugate candidate MRG007, which is used to treat gastrointestinal cancers, outside of Greater China** Lepu will get one-time upfront and near-term milestone payments of $47 mln** Eligible to get up to $1.16 bln in development, regulatory and sales milestones and tiered royalties in high single-digit to low-teen percentages on net sales in Licensed Region** AVBP rose 3.7% on Tuesday** Lepu fell ~38% last year  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nL2N3OI02B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139","BK1161","02157"],"gpt_icon":0},{"id":"2505753471","title":"BRIEF-Lepu Biopharma Says Exclusive License Agreement For Novel Adc Mrg007","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753471","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505753471?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:39","pubTimestamp":1737509992,"startTime":"0","endTime":"0","summary":"BRIEF-Lepu Biopharma Says Exclusive License Agreement For Novel Adc Mrg007Jan 22 (Reuters) - Lepu Biopharma 2157.HK:EXCLUSIVE LICENSE AGREEMENT FOR NOVEL ADC MRG007DEAL WITH ARRIVENT BIOPHARMA, INCFurther company coverage: 2157.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH239:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","02157","BK4139","BK1161"],"gpt_icon":0},{"id":"2505573435","title":"BRIEF-Arrivent Biopharma Enters Exclusive License With Lepu Biopharma For Mrg007, An Antibody Drug Conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2505573435","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505573435?lang=en_us&edition=fundamental","pubTime":"2025-01-22 08:02","pubTimestamp":1737504135,"startTime":"0","endTime":"0","summary":"BRIEF-Arrivent Biopharma Enters Exclusive License With Lepu Biopharma For Mrg007, An Antibody Drug ConjugateJan 21 (Reuters) - Lepu Biopharma Co Ltd 2157.HK:ENTERS EXCLUSIVE LICENSE WITH LEPU BIOPHARM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH20O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK1161","02157","BK4139"],"gpt_icon":0},{"id":"2505734339","title":"Lepu Biopharma Co Ltd -Exclusive License Agreement for Novel ADC Mrg007","url":"https://stock-news.laohu8.com/highlight/detail?id=2505734339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505734339?lang=en_us&edition=fundamental","pubTime":"2025-01-22 08:00","pubTimestamp":1737504055,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH239:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","02157","BK4139","BK1161"],"gpt_icon":0},{"id":"2505734332","title":"Arrivent Biopharma Enters Exclusive License With Lepu Biopharma for Mrg007, an Antibody Drug Conjugate for the Treatment of Gastrointestinal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2505734332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505734332?lang=en_us&edition=fundamental","pubTime":"2025-01-22 08:00","pubTimestamp":1737504043,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH20O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","02157","BK4139","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-03","symbol":"AVBP","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2024-11-14","symbol":"AVBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742443200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2025-04-30","current":-8.832851,"percent":0.700337,"low":-15.980041,"twenty":-11.98007,"median":-10.667127,"eighty":-8.330997,"high":-6.888779,"avg":-10.371093,"sd":1.908817,"marketCap":710938517},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-04-30","current":-8.832851,"twenty":-11.98007,"median":-10.667127,"eighty":-8.330997,"marketCap":710938517}],"updateTime":1746102911665}}}